B-intervention	0	7	Topical
I-intervention	8	18	hyaluronic
I-intervention	19	23	acid
O	24	26	vs
O	26	27	.
B-control	28	36	standard
I-control	37	39	of
I-control	40	44	care
O	45	48	for
O	49	52	the
O	53	63	prevention
O	64	66	of
B-condition	67	76	radiation
I-condition	77	87	dermatitis
O	88	93	after
O	94	102	adjuvant
O	103	115	radiotherapy
O	116	119	for
O	120	126	breast
O	127	133	cancer
O	133	134	:
O	135	141	single
O	141	142	-
O	142	147	blind
O	148	158	randomized
O	159	164	phase
O	165	168	III
O	169	177	clinical
O	178	183	trial
O	183	184	.

O	185	187	To
O	188	197	determine
O	198	201	the
O	202	210	efficacy
O	211	213	of
O	214	216	an
O	217	225	emulsion
O	226	236	containing
O	237	247	hyaluronic
O	248	252	acid
O	253	255	to
O	256	262	reduce
O	263	266	the
O	267	278	development
O	279	281	of
O	282	283	≥
O	284	289	Grade
O	290	291	2
O	292	301	radiation
O	302	312	dermatitis
O	313	318	after
O	319	327	adjuvant
O	328	334	breast
O	335	344	radiation
O	345	353	compared
O	354	358	with
O	359	363	best
O	364	374	supportive
O	375	379	care
O	379	380	.

B-eligibility	381	386	Women
I-eligibility	387	391	with
I-eligibility	392	398	breast
I-eligibility	399	405	cancer
I-eligibility	406	409	who
I-eligibility	410	413	had
I-eligibility	414	423	undergone
I-eligibility	424	434	lumpectomy
I-eligibility	435	438	and
I-eligibility	439	443	were
I-eligibility	444	446	to
I-eligibility	447	454	receive
I-eligibility	455	460	whole
I-eligibility	460	461	-
I-eligibility	461	467	breast
I-eligibility	468	480	radiotherapy
I-eligibility	481	483	to
I-eligibility	484	486	50
I-eligibility	487	489	Gy
I-eligibility	490	494	with
I-eligibility	495	496	a
I-eligibility	497	499	10
I-eligibility	499	500	-
I-eligibility	501	503	to
I-eligibility	504	506	16
I-eligibility	506	507	-
I-eligibility	507	509	Gy
I-eligibility	510	518	surgical
I-eligibility	519	522	bed
I-eligibility	523	528	boost
O	529	533	were
O	534	542	enrolled
O	543	545	in
O	546	547	a
O	548	559	prospective
O	560	570	randomized
O	571	576	trial
O	577	579	to
O	580	587	compare
O	588	591	the
O	592	605	effectiveness
O	606	608	of
O	609	610	a
O	611	621	hyaluronic
O	622	626	acid
O	626	627	-
O	627	632	based
O	633	636	gel
O	637	638	(
O	638	647	RadiaPlex
O	647	648	)
O	649	652	and
O	653	654	a
O	655	665	petrolatum
O	665	666	-
O	666	671	based
O	672	675	gel
O	676	677	(
O	677	685	Aquaphor
O	685	686	)
O	687	690	for
O	691	701	preventing
O	702	705	the
O	706	717	development
O	718	720	of
O	721	731	dermatitis
O	731	732	.

O	733	737	Each
O	738	745	patient
O	746	749	was
O	750	758	randomly
O	759	767	assigned
O	768	770	to
O	771	774	use
O	775	785	hyaluronic
O	786	790	acid
O	791	794	gel
O	795	797	on
O	798	801	the
O	802	808	medial
O	809	813	half
O	814	816	or
O	817	820	the
O	821	828	lateral
O	829	833	half
O	834	836	of
O	837	840	the
O	841	851	irradiated
O	852	858	breast
O	859	862	and
O	863	865	to
O	866	869	use
O	870	873	the
O	874	881	control
O	882	885	gel
O	886	888	on
O	889	892	the
O	893	898	other
O	899	903	half
O	903	904	.

O	905	915	Dermatitis
O	916	919	was
O	920	926	graded
O	927	933	weekly
O	934	943	according
O	944	946	to
O	947	950	the
O	951	957	Common
O	958	969	Terminology
O	970	978	Criteria
O	979	981	v3
O	981	982	.
O	982	983	0
O	984	986	by
O	987	990	the
O	991	999	treating
O	1000	1009	physician
O	1009	1010	,
O	1011	1014	who
O	1015	1018	was
O	1019	1026	blinded
O	1027	1029	as
O	1030	1032	to
O	1033	1038	which
O	1039	1042	gel
O	1043	1046	was
O	1047	1051	used
O	1052	1054	on
O	1055	1060	which
O	1061	1065	area
O	1066	1068	of
O	1069	1072	the
O	1073	1079	breast
O	1079	1080	.

O	1081	1084	The
O	1085	1092	primary
O	1093	1101	endpoint
O	1102	1105	was
B-outcome-Measure	1106	1117	development
I-outcome-Measure	1118	1120	of
I-outcome-Measure	1121	1122	≥
I-outcome-Measure	1123	1128	Grade
I-outcome-Measure	1129	1130	2
I-outcome-Measure	1131	1141	dermatitis
O	1141	1142	.

O	1143	1146	The
O	1147	1152	study
O	1153	1159	closed
O	1160	1165	early
O	1166	1168	on
O	1169	1172	the
O	1173	1178	basis
O	1179	1181	of
O	1182	1183	a
O	1184	1198	recommendation
O	1199	1203	from
O	1204	1207	the
O	1208	1212	Data
O	1213	1216	and
O	1217	1223	Safety
O	1224	1234	Monitoring
O	1235	1240	Board
O	1241	1246	after
B-total-participants	1247	1249	74
O	1250	1252	of
O	1253	1256	the
O	1257	1264	planned
O	1265	1267	92
O	1268	1276	patients
O	1277	1281	were
O	1282	1290	enrolled
O	1290	1291	.

O	1292	1298	Breast
O	1299	1303	skin
O	1304	1311	treated
O	1312	1316	with
O	1317	1320	the
O	1321	1331	hyaluronic
O	1332	1336	acid
O	1337	1340	gel
O	1341	1350	developed
O	1351	1352	a
O	1353	1366	significantly
O	1367	1373	higher
B-outcome	1374	1378	rate
I-outcome	1379	1381	of
I-outcome	1382	1383	≥
I-outcome	1384	1389	Grade
I-outcome	1390	1391	2
I-outcome	1392	1402	dermatitis
O	1403	1407	than
O	1408	1411	did
O	1412	1416	skin
O	1417	1424	treated
O	1425	1429	with
O	1430	1440	petrolatum
O	1441	1444	gel
O	1444	1445	:
B-iv-bin-percent	1446	1448	61
I-iv-bin-percent	1448	1449	.
I-iv-bin-percent	1449	1450	5
I-iv-bin-percent	1450	1451	%
O	1452	1453	(
B-iv-bin-abs	1453	1455	40
O	1455	1456	/
B-intervention-participants	1456	1458	65
O	1458	1459	)
O	1460	1462	vs
O	1462	1463	.
B-cv-bin-percent	1464	1466	47
I-cv-bin-percent	1466	1467	.
I-cv-bin-percent	1467	1468	7
I-cv-bin-percent	1468	1469	%
O	1470	1471	(
B-cv-bin-abs	1471	1473	31
O	1473	1474	/
B-control-participants	1474	1476	65
O	1476	1477	)
O	1478	1479	(
O	1479	1480	p
O	1481	1482	=
O	1483	1484	0
O	1484	1485	.
O	1485	1488	027
O	1488	1489	)
O	1489	1490	.

O	1491	1495	Only
B-iv-bin-abs	1496	1499	one
O	1500	1507	patient
O	1508	1517	developed
B-outcome	1518	1523	Grade
I-outcome	1524	1525	3
I-outcome	1526	1536	dermatitis
O	1537	1542	using
O	1543	1549	either
O	1550	1553	gel
O	1553	1554	.

O	1555	1556	A
O	1557	1563	higher
O	1564	1574	proportion
O	1575	1577	of
O	1578	1586	patients
O	1587	1590	had
B-outcome	1591	1596	worse
I-outcome	1597	1607	dermatitis
O	1608	1610	in
O	1611	1614	the
O	1615	1621	breast
O	1622	1629	segment
O	1630	1637	treated
O	1638	1642	with
O	1643	1653	hyaluronic
O	1654	1658	acid
O	1659	1662	gel
O	1663	1667	than
O	1668	1670	in
O	1671	1675	that
O	1676	1683	treated
O	1684	1688	with
O	1689	1699	petrolatum
O	1700	1703	gel
O	1704	1706	at
O	1707	1710	the
O	1711	1714	end
O	1715	1717	of
O	1718	1730	radiotherapy
O	1731	1732	(
B-iv-bin-percent	1732	1734	42
I-iv-bin-percent	1734	1735	%
O	1736	1738	vs
O	1738	1739	.
B-cv-bin-percent	1740	1742	14
I-cv-bin-percent	1742	1743	%
O	1743	1744	,
O	1745	1746	p
O	1747	1748	=
O	1749	1750	0
O	1750	1751	.
O	1751	1754	003
O	1754	1755	)
O	1755	1756	.

O	1757	1759	We
O	1760	1765	found
O	1766	1768	no
O	1769	1776	benefit
O	1777	1781	from
O	1782	1785	the
O	1786	1789	use
O	1790	1792	of
O	1793	1794	a
O	1795	1802	topical
O	1803	1813	hyaluronic
O	1814	1818	acid
O	1818	1819	-
O	1819	1824	based
O	1825	1828	gel
O	1829	1832	for
O	1833	1841	reducing
O	1842	1845	the
O	1846	1857	development
O	1858	1860	of
O	1861	1862	≥
O	1863	1868	Grade
O	1869	1870	2
O	1871	1881	dermatitis
O	1882	1887	after
O	1888	1896	adjuvant
O	1897	1909	radiotherapy
O	1910	1913	for
O	1914	1920	breast
O	1921	1927	cancer
O	1927	1928	.

O	1929	1939	Additional
O	1940	1947	studies
O	1948	1951	are
O	1952	1958	needed
O	1959	1961	to
O	1962	1971	determine
O	1972	1975	the
O	1976	1984	efficacy
O	1985	1987	of
O	1988	1998	hyaluronic
O	1999	2003	acid
O	2003	2004	-
O	2004	2009	based
O	2010	2013	gel
O	2014	2016	in
O	2017	2028	controlling
O	2029	2038	radiation
O	2039	2049	dermatitis
O	2050	2058	symptoms
O	2059	2064	after
O	2065	2069	they
O	2070	2077	develop
O	2077	2078	.
